

# **BioSpecifics Technologies Corp. Announces Data Presentations at Upcoming XVI Annual Federation of the European Societies for Surgery of the Hand Meeting**

LYNBROOK, NY – May 18, 2011 – BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that there will be three separate presentations on collagenase clostridium histolyticum (trademarked XIAPEX® in Europe) for the treatment of patients suffering from Dupuytren's contracture at the upcoming XVI Annual Federation of the European Societies for Surgery of the Hand Meeting to be held in Oslo, Norway at the Oslo Congress Centre on May 26-28, 2011.

## **The presentations will take place as follows:**

### **Friday, May 27<sup>th</sup>, 2011, 2:24 PM CEST (8:24 AM EDT)**

Location: Hall A, OPS 140 / A-0287

Session 13: Dupuytren's

Presentation Title: Efficacy and tolerability of collagenase clostridium histolyticum in European patients with Dupuytren's contracture: Results from a multicenter, open-label study

Presenters: J. Witthaut, S. Wilbrand, R. Milner, C. Bainbridge, D.E. Boyce, H. Kushner, R.A. Gerber, P. Szczypa (Sweden)

### **Friday, May 27<sup>th</sup>, 2011, 2:32 PM CEST (8:32 AM EDT)**

Location: Hall A, OPS 141 / A-0292

Session 13: Dupuytren's

Presentation Title: Collagenase clostridium histolyticum for the treatment of Dupuytren's contracture: Mechanism of action and tissue effects

Presenters: P. Szczypa, R. Gerber, FTD Kaplan, A. Cole, SGE Hart (UK)

### **Friday, May 27<sup>th</sup>, 2011, 2:40 PM CEST (8:40 AM EDT)**

Location: Hall A, OPS 142 / A-0299

Session 13: Dupuytren's

Presentation Title: Efficacy and safety of collagenase clostridium histolyticum (CCH) in patients who had previous hand surgery

Presenters: C. Bainbridge, RA Gerber, P. Szczypa, B Cohen, M-P Hellio Le Graverand (UK)

## **About Collagenase**

Collagenase is an enzyme that breaks down collagen and is the only protease that can hydrolyze the triple helical region of collagen under physiological conditions. The specific substrate collagen comprises approximately one-third of the total protein in mammalian organisms, and it is the main constituent of skin, tendon and cartilage, as well as the organic component of teeth and bone. The body relies on endogenous collagenase production to remove dead tissue, and collagenase production is an essential biological mechanism that regulates matrix remodeling and the normal turnover of tissue. The Clostridial collagenase produced by BioSpecifics has a broad specificity towards all types of collagen and is acknowledged as much more efficient than mammalian collagenases. Clostridial collagenase cleaves the collagen molecule at multiple sites along the triple helix, whereas the mammalian collagenase is only able to cleave the molecule at a single site along the triple helix. Because collagenase does not damage the cell membrane, it is widely used for cell dispersion for tissue disassociation and cell culture.

There are a number of medical conditions that can result from an excess accumulation of collagen. Collagenase offers a minimally invasive treatment option for patients and can be administered in an office setting. It holds considerable therapeutic potential to change the way patients are treated for a variety of diseases and indications.

#### **About F.E.S.S.H.**

The Federation of European Societies for Surgery of the Hand (F.E.S.S.H.) is an organization which represents national hand surgery societies in Europe. Its object is to improve the standard of hand surgery throughout Europe. It seeks to develop surgical resources by advising European authorities of the requirements and appropriate quality of hand care.

The purpose of F.E.S.S.H. is to rationalize and unify the training and educational structure for qualification of European hand surgery specialists. The standard would be the amount and level of knowledge approved for the specialty of hand surgery within Europe.

#### **About BioSpecifics Technologies Corp.**

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications, three of which include: Dupuytren's contracture, Peyronie's disease, and frozen shoulder (adhesive capsulitis). Its strategic partner Auxilium Pharmaceuticals, Inc. markets XIAFLEX<sup>®</sup> in the U.S. for the treatment of Dupuytren's contracture. Pfizer, Inc. is responsible for marketing XIAPEX<sup>®</sup> in Europe and has announced European regulatory approval and the first commercial sale in the United Kingdom. Asahi Kasei Pharma Corporation is responsible for marketing XIAFLEX<sup>®</sup> in Japan. More information about BioSpecifics Technologies Corp. may be found on its website at [www.biospecifics.com](http://www.biospecifics.com).

## **Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding BioSpecifics' strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, its expected revenue growth, and any other statements containing the words "believes," "expects," "anticipates," "plans," "estimates" and similar expressions, are forward-looking statements. There are a number of important factors that could cause its actual results to differ materially from those indicated by such forward-looking statements, including the statements made by BioSpecifics and by its partner Auxilium regarding progress toward achievement of Auxilium's objectives for the US launch of XIAFLEX<sup>®</sup> for Dupuytren's contracture; the ability of Pfizer to achieve its objectives for XIAPEX<sup>®</sup> in Europe; the ability of Asahi Kasei to achieve its objectives for XIAFLEX<sup>®</sup> in Japan; the success of the Phase 3 trials for XIAFLEX for the treatment of Peyronie's disease; the outcome of the dispute with Auxilium over the Company's right to conduct clinical trials; the Company's ability to restart the Chien-803 trial for injectable collagenase for the treatment of canine lipomas and the clinical success of that trial; the Company's ability to initiate and complete clinical trials in additional indications, all of which will determine the amount of milestone, royalty and sublicense income BioSpecifics may receive; and other risk factors identified in the Company's Form 10-K for the year ended December 31, 2010 and its reports on Form 8-K filed with the SEC. All forward-looking statements included in this press release are made as of the date hereof, and the Company assumes no obligation to update these forward-looking statements.

### **Contact:**

BioSpecifics Technologies Corp.

Thomas L. Wegman, President

(516) 593-7000

[thomas\\_wegman@biospecifics.com](mailto:thomas_wegman@biospecifics.com)